Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St Jude CE marks Penta neurostimulation lead; also approved in Australia

This article was originally published in Clinica

Executive Summary

St Jude Medical has CE marked its Penta surgical lead for neurostimulation therapy. The company has also obtained regulatory and reimbursement approval from the Australian Therapeutic Goods Administration (TGA) for the device. The lead is designed to treat chronic pain of the trunk and limbs and pain from back surgeries that have failed. It delivers mild electrical pulses to interrupt or mask the transmission of pain signals to the brain. Electrodes on the lead can be programmed to meet individual patients' needs. The St Paul, Minnesota-based company claims that the five-column surgical lead is the first of its kind, and features the smallest electrodes on the market. The Penta lead gained US premarket approval (PMA) last year (www.clinica.co.uk, 7 December 2009).

You may also be interested in...



Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel